Aziz Shaikh Irfan, Khattak Muhammad Adnan, Usmani Zafar, Ladipeerla Narsing, Pittman Ken
Department of Endocrinology, The Queen Elizabeth Hospital, Adelaide, Australia.
BMJ Case Rep. 2011 Aug 4;2011:bcr0420102917. doi: 10.1136/bcr.04.2010.2917.
Small cell lung cancer (SCLC) with ectopic adrenocorticotropic hormone (ACTH) syndrome and resultant hypercortisolism carries a poor prognosis with a short median survival and high incidence of infective complications. The combination of etoposide with either carboplatin or cisplatin is the current standard chemotherapy used for the management of SCLC. Etoposide is metabolised by cytochrome P450 3A4. Ketoconazole is an imidazole derivative possessing antifungal properties and also causes inhibition of adrenal corticosteroid and androgen production. There is an additional increased risk of toxicity due to a potential interaction between etoposide and ketoconazole, which is a strong inhibitor of cytochrome P450 3A4, and theoretically can lead to greater myelosuppression. Metyrapone can be a safe alternative in such settings.
伴有异位促肾上腺皮质激素(ACTH)综合征及由此导致的皮质醇增多症的小细胞肺癌(SCLC)预后较差,中位生存期短,感染并发症发生率高。依托泊苷联合卡铂或顺铂是目前用于治疗SCLC的标准化疗方案。依托泊苷由细胞色素P450 3A4代谢。酮康唑是一种具有抗真菌特性的咪唑衍生物,还可抑制肾上腺皮质类固醇和雄激素的生成。依托泊苷与酮康唑之间可能存在相互作用,酮康唑是细胞色素P450 3A4的强效抑制剂,理论上可导致更强的骨髓抑制,从而使毒性风险进一步增加。在这种情况下,甲吡酮可能是一种安全的替代药物。